Iaso Biotherapeutics is a clinical-stage Chinese biopharmaceutical company focused on discovering, developing, and manufacturing innovative cell therapies and antibody products. Its core platforms include a fully human antibody discovery platform (IMARS), a high-throughput CAR-T screening platform, and proprietary manufacturing processes. The company has a diversified clinical-stage pipeline of over 10 novel autologous and allogeneic CAR-T and biologics candidates, led by Equecabtagene Autoleucel (CT103A), a fully human BCMA CAR-T injection. Equecabtagene Autoleucel has received NDA acceptance from China’s NMPA for relapsed/refractory multiple myeloma and IND approval from the U.S. FDA; it also received NMPA Breakthrough Therapy Designation (Feb 2021) and FDA Orphan Drug Designation (Feb 2022). The company has an in-house CD19/CD22 dual-targeted CAR-T that holds two IND clearances for r/r B-NHL and r/r B-ALL and is in a Phase I trial for r/r B-NHL; that program received FDA ODD in Oct 2021. The recent financing is intended to support R&D across the pipeline and the commercial launch of Equecabtagene Autoleucel. IASO Biotherapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and manufacturing novel cell therapies and biologics for oncology and autoimmune diseases. The company leverages proprietary platforms including a fully human antibody discovery platform (IMARS), a high-throughput CAR-T drug discovery platform, and proprietary manufacturing processes. IASO Bio’s pipeline includes multiple autologous and allogeneic CAR-T and biologics candidates—a diversified portfolio of eight novel pipeline products—with lead asset CT103A (anti-BCMA CAR-T) in a pivotal trial for relapsed/refractory multiple myeloma. Its fully human CD19/CD22 dual-targeted CAR-T received NMPA IND clearances in July 2021 and a fully human CD5 CAR-T has completed preclinical work and is in pre-IND stage. The company plans to use new proceeds to accelerate global development and regulatory submissions, build a broader universal allogeneic cell-therapy pipeline including products for solid tumors, expand global strategic partnerships, and advance CT103A into frontline, combination, indication-expansion, and overseas development. Iaso Biotherapeutics is a clinical-stage biotech focused on development of innovative cell therapies for cancer, including autologous and universal CAR-T products for hematological tumors and TCR-like CAR-T candidates for certain solid tumors. The company is developing more than 10 pipeline products, all based on fully human sequences, and maintains a proprietary phage display library (>2×10^11) to support fully-human antibody discovery. Iaso Bio also operates in-house plasmid, lentivirus and CAR-T production technology platforms capable of supporting IND submissions and clinical research for multiple products. In September 2019 the company received NMPA approval of a phase Ib/II IND for CT103A, an anti-BCMA CAR-T co-developed with Innovent Biologics, and several new candidates are in preclinical stages or investigator-initiated trials. The company plans to use new financing to expand its pipeline, advance regulatory applications and clinical trials in China and the United States, improve its fully-human antibody development platform, grow cooperation with international R&D institutions, and accelerate construction of commercial facilities. Iaso Bio was founded in March 2017 and is based in Nanjing, China.

Total raised

$242M

Funding rounds

3

Latest round

Series C

Latest activity

Jan 2023